Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Methodist Charlton Cancer Ctr.
mi
from
Dallas, TX
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Methodist Charlton Cancer Ctr.
mi
from
Dallas, TX
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Texas Cancer Center
mi
from
Denton, TX
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Texas Cancer Center
mi
from
Denton, TX
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
El Paso Cancer Treatment Center
mi
from
El Paso, TX
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
El Paso Cancer Treatment Center
mi
from
El Paso, TX
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Texas Oncology P.A.
mi
from
Fort Worth, TX
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Texas Oncology P.A.
mi
from
Fort Worth, TX
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Texas Oncology PA
mi
from
Garland, TX
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Texas Oncology PA
mi
from
Garland, TX
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Texas Oncology
mi
from
Houston, TX
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Texas Oncology
mi
from
Houston, TX
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Lake Vista Cancer Center
mi
from
Lewisville, TX
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Lake Vista Cancer Center
mi
from
Lewisville, TX
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Longview Cancer Center
mi
from
Longview, TX
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Longview Cancer Center
mi
from
Longview, TX
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
South Texas Cancer Center - McAllen
mi
from
McAllen, TX
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
South Texas Cancer Center - McAllen
mi
from
McAllen, TX
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Texas Cancer Center of Mesquite
mi
from
Mesquite, TX
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Texas Cancer Center of Mesquite
mi
from
Mesquite, TX
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Allison Cancer Center
mi
from
Midland, TX
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Allison Cancer Center
mi
from
Midland, TX
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Texas Oncology - Odessa
mi
from
Odessa, TX
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Texas Oncology - Odessa
mi
from
Odessa, TX
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Paris Regional Cancer Center
mi
from
Paris, TX
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Paris Regional Cancer Center
mi
from
Paris, TX
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
South Texas Oncology and Hematology
mi
from
San Antonio, TX
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
South Texas Oncology and Hematology
mi
from
San Antonio, TX
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
San Antonio Tumor and Blood Clinic
mi
from
San Antonio, TX
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
San Antonio Tumor and Blood Clinic
mi
from
San Antonio, TX
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
HOAST-Medical Dr.
mi
from
San Antonio, TX
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
HOAST-Medical Dr.
mi
from
San Antonio, TX
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Texas Cancer Center - Sherman
mi
from
Sherman, TX
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Texas Cancer Center - Sherman
mi
from
Sherman, TX
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Texas Oncology Cancer Center - Sugar Land
mi
from
Sugar Land, TX
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Texas Oncology Cancer Center - Sugar Land
mi
from
Sugar Land, TX
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Tyler Cancer Center
mi
from
Tyler, TX
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Tyler Cancer Center
mi
from
Tyler, TX
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Texas Oncology Cancer Care and Research
mi
from
Waco, TX
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Texas Oncology Cancer Care and Research
mi
from
Waco, TX
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Texas Oncology, P.A.
mi
from
Webster, TX
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Texas Oncology, P.A.
mi
from
Webster, TX
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Texoma Cancer Center
mi
from
Wichita Falls, TX
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Texoma Cancer Center
mi
from
Wichita Falls, TX
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Fairfax Northern VA Hem-Onc PC
mi
from
Fairfax, VA
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Fairfax Northern VA Hem-Onc PC
mi
from
Fairfax, VA
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Virginia Oncology Associates
mi
from
Norfolk, VA
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Virginia Cancer Institute
mi
from
Richmond, VA
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Virginia Cancer Institute
mi
from
Richmond, VA
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Onc and Hem Associates os SW VA, Inc.
mi
from
Salem, VA
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Onc and Hem Associates os SW VA, Inc.
mi
from
Salem, VA
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Highline Medical Oncology
mi
from
Burien, WA
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Highline Medical Oncology
mi
from
Burien, WA
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Pudget Sound Cancer Center-Edmonds
mi
from
Edmonds, WA
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Pudget Sound Cancer Center-Edmonds
mi
from
Edmonds, WA
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Kadlec Hematology & Oncology
mi
from
Kennewick, WA
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Kadlec Hematology & Oncology
mi
from
Kennewick, WA
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Puget Sound Cancer Center - Seattle
mi
from
Seattle, WA
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Puget Sound Cancer Center - Seattle
mi
from
Seattle, WA
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Cancer Care Northwest-South
mi
from
Spokane, WA
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Cancer Care Northwest-South
mi
from
Spokane, WA
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Northwest Cancer Specialists-Vancouver
mi
from
Vancouver, WA
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Northwest Cancer Specialists-Vancouver
mi
from
Vancouver, WA
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Yakima Valley Mem Hosp/North Star Lodge
mi
from
Yakima, WA
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Yakima Valley Mem Hosp/North Star Lodge
mi
from
Yakima, WA
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Yakima Valley Memorial Hospital/North Star Lodge
mi
from
Yakima, WA
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Yakima Valley Memorial Hospital/North Star Lodge
mi
from
Yakima, WA
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Raleigh Regional Cancer Center
mi
from
Beckley, WV
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Raleigh Regional Cancer Center
mi
from
Beckley, WV
Click here to add this to my saved trials
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Arch Medical Services
mi
from
Saint Louis, MO
TAC Versus TC for Adjuvant Breast Cancer
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Arch Medical Services
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer
A Phase II Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU 0059436 (Olaparib) Given Orally Twice Daily in Patients With Advanced BRCA1 or BRCA2 Associated Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer
A Phase II Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU 0059436 (Olaparib) Given Orally Twice Daily in Patients With Advanced BRCA1 or BRCA2 Associated Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer
A Phase II Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU 0059436 (Olaparib) Given Orally Twice Daily in Patients With Advanced BRCA1 or BRCA2 Associated Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer
A Phase II Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU 0059436 (Olaparib) Given Orally Twice Daily in Patients With Advanced BRCA1 or BRCA2 Associated Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer
A Phase II Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU 0059436 (Olaparib) Given Orally Twice Daily in Patients With Advanced BRCA1 or BRCA2 Associated Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New York, NY
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer
A Phase II Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU 0059436 (Olaparib) Given Orally Twice Daily in Patients With Advanced BRCA1 or BRCA2 Associated Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer
A Phase II Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU 0059436 (Olaparib) Given Orally Twice Daily in Patients With Advanced BRCA1 or BRCA2 Associated Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer
A Phase II Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU 0059436 (Olaparib) Given Orally Twice Daily in Patients With Advanced BRCA1 or BRCA2 Associated Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer
A Phase II Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU 0059436 (Olaparib) Given Orally Twice Daily in Patients With Advanced BRCA1 or BRCA2 Associated Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer
A Phase II Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU 0059436 (Olaparib) Given Orally Twice Daily in Patients With Advanced BRCA1 or BRCA2 Associated Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer
A Phase II Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU 0059436 (Olaparib) Given Orally Twice Daily in Patients With Advanced BRCA1 or BRCA2 Associated Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Melbourne,
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer
A Phase II Open-label, Non-comparative, International, Multicentre Study to Assess the Efficacy and Safety of KU 0059436 (Olaparib) Given Orally Twice Daily in Patients With Advanced BRCA1 or BRCA2 Associated Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Melbourne,
Click here to add this to my saved trials
Weight Gain Prevention for Breast Cancer Survivors
Weight Gain Prevention for Breast Cancer Survivors
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Weight Gain Prevention for Breast Cancer Survivors
Weight Gain Prevention for Breast Cancer Survivors
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Meditation and Cognitive Function in Women With Breast Cancer
Feasibility Study of Meditation, Cognitive Function, and Quality of Life in Women With Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Meditation and Cognitive Function in Women With Breast Cancer
Feasibility Study of Meditation, Cognitive Function, and Quality of Life in Women With Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Status: Enrolling
Updated:  12/31/1969
NEA Clinic
mi
from
Jonesboro, AR
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Status: Enrolling
Updated: 12/31/1969
NEA Clinic
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Status: Enrolling
Updated:  12/31/1969
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Status: Enrolling
Updated: 12/31/1969
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Status: Enrolling
Updated:  12/31/1969
Highlands Oncology Group
mi
from
Springdale, AR
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Status: Enrolling
Updated: 12/31/1969
Highlands Oncology Group
mi
from
Springdale, AR
Click here to add this to my saved trials
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Status: Enrolling
Updated:  12/31/1969
Emory University
mi
from
Atlanta, GA
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Status: Enrolling
Updated: 12/31/1969
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Status: Enrolling
Updated:  12/31/1969
St. Luke'S Cancer Institute
mi
from
Kansas City, MO
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Status: Enrolling
Updated: 12/31/1969
St. Luke'S Cancer Institute
mi
from
Kansas City, MO
Click here to add this to my saved trials
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Status: Enrolling
Updated:  12/31/1969
Hackensack University
mi
from
Hackensack, NJ
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
Status: Enrolling
Updated: 12/31/1969
Hackensack University
mi
from
Hackensack, NJ
Click here to add this to my saved trials